BioStem CCO acquires 500 shares via RSUs
BioStem’s Chief Commercial Officer converted 500 RSUs into common stock and retains substantial option and RSU holdings with multi‑year vesting schedules.
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) reports that Chief Commercial Officer Barry Hassett settled 500 restricted stock units into 500 shares of common stock on September 9, 2026, at a reported price of $0.000 per share, resulting in 5,003 common shares held directly after the transaction. The RSU settlement corresponds to units where each RSU represents a contingent right to receive one share of common stock and vesting occurs in quarterly installments over four years from the December 9, 2024 grant date. Hassett also continues to hold several stock option awards and additional RSUs with various vesting schedules extending through February 2029 and option expirations running between 2035 and 2036, indicating ongoing equity-based compensation. No Rule 10b5-1 trading plan is reported for these transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
500 shares exercised/converted
Exercise
7 txns
Insider
HASSETT BARRY
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F4, F5 | 500 | $0.00 | $0.00 |
| Exercise | Common Stock | 500 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Restricted Stock Units F4, F6 | -- | -- | -- |
| holding | Restricted Stock Units F4, F7 | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 64,198 contracts for 59,701 underlying shares (Direct);
Common Stock — 5,003 shares (Direct);
Stock Options (Right to Buy) — 84,329 contracts (Direct)
Footnotes (7)
- F1. These options vest according to the following schedule: 33% vested on February 1, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F2. These options vest according to the following schedule: 33%% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F3. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F4. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F5. These restricted stock units vest in equal quarterly installments over four years from the grant date (December 9, 2024).
- F6. These restricted stock units vest according to the following schedule: 33% vested on February 1, 2026, the one-year anniversary of the grant date, with the remaining unites vesting in equal quarterly installments over the subsequent two year period.
- F7. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Key Figures
RSUs settled: 500 units
Common shares acquired: 500 shares
Common shares held after transaction: 5,003 shares
+5 more
8 metrics
RSUs settled
500 units
Restricted stock units converted into common stock on September 9, 2026
Common shares acquired
500 shares
Shares received upon RSU settlement on September 9, 2026
Common shares held after transaction
5,003 shares
Direct ownership after September 9, 2026 transaction
Stock options at $14.89 expiring February 1, 2035
11,417 underlying shares
Directly held stock options on BioStem common stock
Stock options at $14.89 expiring October 13, 2035
2,427 underlying shares
Directly held stock options on BioStem common stock
Stock options at $5.50 expiring February 11, 2036
70,485 underlying shares
Directly held stock options on BioStem common stock
RSUs outstanding (block 1)
1,519 underlying shares
Restricted stock units with vesting starting February 1, 2026
RSUs outstanding (block 2)
58,182 underlying shares
Restricted stock units with vesting starting February 11, 2027
Key Terms
Restricted Stock Units, Stock Options (Right to Buy), exercise price, vesting in equal quarterly installments, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an exercise price of $14.8900"
exercise price financial
"exercisePrice: 5.5000 with expiration date February 11, 2036"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting in equal quarterly installments financial
"remaining options vesting in equal quarterly installments over the subsequent two year"
contingent right to receive financial
"Each restricted stock unit represents a contingent right to receive one share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BSEM’s Chief Commercial Officer report in this Form 4?
The Chief Commercial Officer, Barry Hassett, reported the settlement of 500 restricted stock units into 500 shares of BioStem common stock on September 9, 2026, as part of his equity compensation.
What stock options does Barry Hassett hold in BSEM according to this filing?
Barry Hassett holds stock options covering 11,417 shares and 2,427 shares at an exercise price of $14.89, expiring in 2035, and options covering 70,485 shares at an exercise price of $5.50, expiring February 11, 2036.
What RSU positions in BSEM remain outstanding for Barry Hassett?
He has remaining restricted stock units representing 1,519 underlying shares and another block representing 58,182 underlying shares of BioStem common stock, subject to their stated vesting schedules.
Are Barry Hassett’s BSEM transactions under a Rule 10b5-1 plan?
The filing indicates that no Rule 10b5-1 trading plan is reported for these transactions; the document-level checkbox for such a plan is not marked.
How do Hassett’s BSEM options and RSUs vest over time?
The options and RSUs generally vest with 33% on the one-year anniversary of the applicable grant date and the remaining awards vesting in equal quarterly installments over the following two years, as described in the footnotes.
AI-generated analysis. How Rhea-AI works. Not financial advice.
